Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 12/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 4/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1337653 | 0.84 | CCR8 (0.72) | CCR8 | |
| SCHEMBL1341325 | 0.78 | CCR8 (0.68) | CCR8 | |
| SCHEMBL6416838 | 0.75 | CCR8 (0.59) | CCR8 | |
| SCHEMBL6423843 | 0.75 | CCR8 (0.55) | CCR8ALDH1A1 | |
| SCHEMBL1338776 | 0.74 | CCR8 (0.59) | CCR8TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1341332 | 0.73 | CCR8 (0.90) | CCR8MEN1ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL1339809 | 0.73 | CCR8 (0.58) | CCR8 | |
| SCHEMBL12129697 | 0.72 | CCR8 (0.82) | CCR8MEN1ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL1338895 | 0.72 | CCR8 (0.57) | CCR8TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL6250476 | 0.72 | CCR8 (0.49) | CCR8MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050085518-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085518-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | CCR8, CCR1, CCR3 | CCR8 1/4885TAS1R3 280/4885TAS1R1 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.